Zimmer Biomet Q1 net sales $1.831B (+10.1% reported, +13.2% CC); raises FY2023 guidance

ZIMMER BIOMET HOLDINGS, INC.

2023-Q1 EPS reported $1.11 revenue$1,831,000,000

Q1 diluted EPS $1.11 GAAP, adjusted $1.89; net earnings $232.5M GAAP, $396.8M adjusted.
U.S. knee sales $448.2M (+18.1% YoY); hip sales $252.3M (+12.3% YoY).
Raises FY2023 adjusted EPS guidance to $7.40-$7.50 (prior $6.95-$7.15); reported revenue growth 5.0-6.0% (prior 1.5-3.5%).
Completed acquisition of Embody, Inc., adding collagen-based biointegrative solutions to sports medicine.
Launched Persona OsseoTi Keel Tibia for cementless knee replacement; ZBEdge platform enhancements at AAOS 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ZIMMER BIOMET HOLDINGS, INC. reported first quarter ended March 31, 2023 results: revenue $1.831 billion, net income $232.5 million, EPS $1.11.

Period: first quarter ended March 31, 2023
Revenue: $1.831 billion
Net income: $232.5 million
EPS: $1.11
Result: reported results

Exact text from the filing

The Company reported first quarter net sales of $1.831 billion, an increase of 10.1% over the prior year period, and an increase of 13.2% on a constant currency 1 basis. Net earnings for the first quarter were $232.5 million, or $396.8 million on an adjusted 1 basis. Diluted earnings per share were $1.11 for the first quarter, and adjusted 1 diluted earnings per share were $1.89.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ZIMMER BIOMET HOLDINGS, INC. reported full-year 2023 results: EPS $7.40 - $7.50. Guidance raised.

Period: full-year 2023
EPS: $7.40 - $7.50
Guidance: raised
Result: guidance update

Exact text from the filing

Projected Year Ending December 31, 2023 Previous Guidance Updated Guidance 2023 Reported Revenue Change 1.5% - 3.5% 5.0% - 6.0% Foreign Currency Exchange Impact (1.5)% (1.0)% Adjusted Diluted EPS (1) $6.95 - $7.15 $7.40 - $7.50

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

ZIMMER BIOMET HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-016423

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.